Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
BioCardia (BCDA) just unveiled an announcement.
BioCardia, Inc. has kicked off patient enrollment for its critical Phase III CardiAMP Cell Therapy trial, targeting the treatment of chronic ischemic heart failure with reduced ejection fraction. This step marks a significant milestone as the company advances towards potentially offering new hope for patients suffering from this debilitating condition.
See more data about BCDA stock on TipRanks’ Stock Analysis page.
